Bayer HealthCare Pharamcueticals
Partnering
Broad Networking for long-term success
To be able to develop innovative products, a company needs an appropriate environment – in Germany, in Europe and worldwide – and strong partners.
With a global network of external scientific and industrial development partners, we strengthen our own research infrastructure and, therefore, assure the long-term success of our product pipeline.
To supplement our internal efforts, we collaborate with several companies in different stages of the typical pharmaceutical research cycle.
Our more significant collaborations are described (in alphabetical order) in the table below.
Partner Objective
Affymetrix Understanding the disease mechanism and identifying new targets
ARTEMIS Pharmaceuticals GmbH In vivo validation of targets
Astra Zeneca Co-development of the selective estrogen receptor downregulator (SERD) for the treatment of hormonal dependent breast cancer
Avid Radiopharmaceuticals Radiopharmaceuticals compounds
Bausch&Lomb
SEGRA ophthalmology
Celera Genomic Cathepsin S inhibitor drug development program
ChemDiv Synthesis of compounds
ComGenex Synthesis of compounds
Genedata Expressionist software
Genzyme Corporation Campath in chronic lymphocytic leukemia and multiple sclerosis
Inpharmatica Kinase SARfari in Silico Drug Discovery
Johnson & Johnson Development of Rivaroxaban
Monash University New targets for gender health
MorphoSys AG Antibody diagnostics and therapeutics for cancer and other life threatening diseases
Nektar Therapeutics Targeted inhaled antibiotic therapy for pulmonary infections
Neurosciences Victoria Ltd. Treatment of neurodegenerative disorders
Novartis Pharma Research and development of inhibitors of angiogenesis
Nuvelo Development of alfimeprase
Onyx Co-development of Nexavar
Peregrine Pharmaceuticals, Inc. Selective cancer diagnostics (vascular targeting agents)
Philogen S.p.A. Development of immunoconjugates for cancer therapy and diagnosis
Proteros X-ray structure analysis
Regeneron Pharmaceuticals Development of the VEGF Trap for the treatment of eye diseases
Seattle Genetics Increasing the pool of potential drug candidates by biomolecules
Sonus Pharmaceuticals TOCOSOL Paclitaxel
Stanford University/Gambhir New PET tracers
Warner Chilcott SEGRA for dermatology
AI
